Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

The psychedelic revolution is leaving behind people of color

1 articles · 1 outlets · spread 0.00

The psychedelic revolution is leaving behind people of color
psychedelics2 d ago

The psychedelic revolution is leaving behind people of color

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

1 outlet
  • STAT·May 1

    The psychedelic revolution is leaving behind people of color

    Flanked by one of psychedelics’ biggest celebrity cheerleaders, Joe Rogan, and a troupe of MAHA loyalists, President Trump recently signed an executive order aimed at accelerating psychedelic access for clinical research and treatment. Use of naturally occurring and synthetic hallucinogens traces back to the Neanderthals. Yet these substances have long been a pariah in mainstream medicine, written off as “club drugs” with little to no clinical value (or worse, downright negative effects). But they no longer sit on the fringes of medicine. In August, for instance, pharmaceutical giant AbbVie inked a billion-dollar deal, the first of its kind, to acquire Bretisilocin, a psychedelic compound used to treat major depressive disorder. Now Trump is directing federal agencies to streamline regulatory pathways, expand clinical trials, and explore mechanisms for broader therapeutic use. With the federal government formally throwing its hat in the ring, this is likely just the start of a much broader trend of Big Pharma investing heavily in the drugs. As researchers who focus on mental illness and addiction, we see psychedelics’ potential as a form of treatment as virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions — especially when it comes to their benefits

From the Center

0 outlets

No coverage from this perspective yet.

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

STAT

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.